Trevi Therapeutics (TRVI) Misses Q3 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q3 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Active options: MSTR HOOD SPCE AMD NOK META GOOGL ASTS PLTR MARA CRWV SMCI RKLB
• SpaceX (SPCX) reaches new intraday/all-time highs